Skip to content

Assessment of the Rosacea Prevalence in the General Population

Assessment of the Prevalence of Rosacea in the General Population

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02292797
Acronym
RISE
Enrollment
6000
Registered
2014-11-17
Start date
2013-09-30
Completion date
2014-02-28
Last updated
2014-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Brief summary

Multi-centre interventional cross-sectional prevalence study Assessment of the Rosacea Prevalence in the General Population.

Detailed description

Primary objective: Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis

Interventions

OTHERPrevalence assessment

Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis

Sponsors

Galderma R&D
Lead SponsorINDUSTRY

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Part I Inclusion Criteria: The following subjects will be included in the study: * Subjects aged 18 to 65 years old from the general population * Subjects who are willing to complete the questionnaires Part II Inclusion Criteria: The following subjects will be included in Part II of the study: * Subjects who screened positive for rosacea during the first part of the study and selected by random method * Subjects who gave their informed consent to participate in Part II of the study

Design outcomes

Primary

MeasureTime frameDescription
percentage of subjects with rosacea diagnosis confirmedgeneral population will be surveyed over an expected average duration of 6 monthsestimation of the percentage of rosacea patients in the general population

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026